Medigene AG - Asset Resilience Ratio

Latest as of December 2023: 25.22%

Medigene AG (MDG1) has an Asset Resilience Ratio of 25.22% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

€8.00 Million

≈ $9.35 Million USD Cash + Short-term Investments

Total Assets

€31.72 Million

≈ $37.08 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2012–2023)

This chart shows how Medigene AG's Asset Resilience Ratio has changed over time. Check MDG1 PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Medigene AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Medigene AG.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€8.00 Million	25.22%
Total Liquid Assets	€8.00 Million	25.22%

Asset Resilience Insights

Very High Liquidity: Medigene AG maintains exceptional liquid asset reserves at 25.22% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Medigene AG Industry Peers by Asset Resilience Ratio

Compare Medigene AG's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Tubize-Fin BR:TUB	Biotechnology	0.05%
Verona Pharma plc F:I9SA	Biotechnology	0.00%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
Syndax Pharmaceuticals Inc NASDAQ:SNDX	Biotechnology	46.79%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Vor Biopharma Inc NASDAQ:VOR	Biotechnology	63.47%
Chengdu Kanghua Biological Products SHE:300841	Biotechnology	1.19%
Jiangsu Aidea Pharmaceutical Co Ltd SHG:688488	Biotechnology	4.35%

Annual Asset Resilience Ratio for Medigene AG (2012–2023)

The table below shows the annual Asset Resilience Ratio data for Medigene AG.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2023-12-31	25.22%	€8.00 Million ≈ $9.35 Million	€31.72 Million ≈ $37.08 Million	-39.07pp
2022-12-31	64.29%	€33.22 Million ≈ $38.84 Million	€51.68 Million ≈ $60.42 Million	+26.60pp
2021-12-31	37.69%	€22.42 Million ≈ $26.21 Million	€59.47 Million ≈ $69.53 Million	-2.48pp
2020-12-31	40.18%	€30.03 Million ≈ $35.11 Million	€74.75 Million ≈ $87.39 Million	-9.89pp
2019-12-31	50.07%	€54.68 Million ≈ $63.93 Million	€109.22 Million ≈ $127.68 Million	+10.40pp
2018-12-31	39.67%	€51.41 Million ≈ $60.10 Million	€129.59 Million ≈ $151.50 Million	-6.54pp
2017-12-31	46.21%	€51.72 Million ≈ $60.47 Million	€111.94 Million ≈ $130.87 Million	-0.90pp
2016-12-31	47.11%	€52.63 Million ≈ $61.53 Million	€111.72 Million ≈ $130.61 Million	+13.64pp
2015-12-31	33.47%	€38.00 Million ≈ $44.43 Million	€113.53 Million ≈ $132.73 Million	+33.22pp
2014-12-31	0.25%	€180.00K ≈ $210.44K	€71.28 Million ≈ $83.34 Million	-0.04pp
2013-12-31	0.29%	€154.00K ≈ $180.04K	€52.66 Million ≈ $61.56 Million	-0.30pp
2012-12-31	0.59%	€362.00K ≈ $423.22K	€61.26 Million ≈ $71.61 Million	--

pp = percentage points

About Medigene AG

XETRA:MDG1 Germany Biotechnology

Market Cap

$2.30 Million

€1.97 Million EUR

Market Cap Rank

#30008 Global

#2607 in Germany

Share Price

€0.13

Change (1 day)

+0.00%

52-Week Range

€0.13 - €0.13

All Time High

€36.05